ELMS STEVE 4

Accession 0001140361-25-022713

CIK 0001368514other

View on SEC.gov Company Profile

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 9:00 PM ET

Size

43.8 KB

Accession

0001140361-25-022713

Insider Transaction Report

Form 4

Period: 2025-06-12

ADMA BIOLOGICS, INC.ADMA

ELMS STEVE

Director

Transactions

Exercise/Conversion
Common Stock
2025-06-13$3.66/sh+53,837$197,043→ 160,167 total
Exercise/Conversion
Common Stock
2025-06-13$3.89/sh+30,000$116,700→ 207,667 total
Exercise/Conversion
Common Stock
2025-06-13$3.35/sh+51,630$172,961→ 382,469 total
Sale
Common Stock
2025-06-13$20.82/sh−137,931$2,871,723→ 282,079 total
Sale
Common Stock
2025-06-16$20.24/sh−194,749$3,941,720→ 87,330 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−51,630→ 0 total
Exercise: $3.35Exp: 2033-03-06→ Common Stock (51,630 underlying)
Exercise/Conversion
Common Stock
2025-06-13$5.00/sh+10,000$50,000→ 106,330 total
Sale
Common Stock
2025-06-12$21.69/sh−92,941$2,015,890→ 2,031,730 total(indirect: See footnote)
Exercise/Conversion
Common Stock
2025-06-13$2.92/sh+15,000$43,725→ 222,667 total
Exercise/Conversion
Common Stock
2025-06-13$1.67/sh+53,172$88,797→ 330,839 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−9,000→ 0 total
Exercise: $5.96Exp: 2026-01-28→ Common Stock (9,000 underlying)
Exercise/Conversion
Common Stock
2025-06-13$5.96/sh+9,000$53,640→ 96,330 total
Exercise/Conversion
Common Stock
2025-06-13$4.91/sh+17,500$85,925→ 177,667 total
Exercise/Conversion
Common Stock
2025-06-13$2.35/sh+55,000$129,250→ 277,667 total
Exercise/Conversion
Common Stock
2025-06-13$5.40/sh+37,541$202,721→ 420,010 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−10,000→ 0 total
Exercise: $5.00Exp: 2027-02-14→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−53,837→ 0 total
Exercise: $3.66Exp: 2027-06-06→ Common Stock (53,837 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−17,500→ 0 total
Exercise: $4.91Exp: 2028-06-22→ Common Stock (17,500 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−30,000→ 0 total
Exercise: $3.89Exp: 2029-03-13→ Common Stock (30,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−15,000→ 0 total
Exercise: $2.92Exp: 2030-02-28→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−55,000→ 0 total
Exercise: $2.35Exp: 2031-02-25→ Common Stock (55,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−53,172→ 0 total
Exercise: $1.67Exp: 2032-03-07→ Common Stock (53,172 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-13−37,541→ 0 total
Exercise: $5.40Exp: 2034-02-26→ Common Stock (37,541 underlying)

Footnotes (8)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $22.17, inclusive. The reporting person undertakes to provide to ADMA Biologics, Inc. (the "Issuer"), any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (5).
[F2]These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.39, inclusive.
[F4]Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 271,190 shares of common stock owned by the reporting person.
[F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.40, inclusive.
[F6]Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 76,441 shares of common stock owned by the reporting person.
[F7]These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.
[F8]These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Documents

1 file

4
form4.xmlPrimary
FORM 4

Issuer

ADMA BIOLOGICS, INC.

CIK 0001368514

→

Entity typeother

Related Parties

filerCIK 0001250195

Filing Metadata

Form type: 4
Filed: Jun 15, 8:00 PM ET
Accepted: Jun 16, 9:00 PM ET
Size: 43.8 KB

View on SEC.gov